Retrospective analysis reveals delayed engraftment in CMV-seropositive recipients with letermovir use, suggesting vigilance is needed.
Although letermovir prophylaxis has drastically reduced cytomegalovirus (CMV) infections in allogeneic hematopoietic cell transplantation recipients (allo-HCTR), the broader impact of letermovir prophylaxis remains unclear. We retrospectively analyzed hematological outcomes in CMV-seropositive allo-HCTR (R+) from the pre- and letermovir periods. Among 314 consecutive allo-HCTR+, engraftment was significantly delayed in allo-HCTR+ in the letermovir period, even after removing potential confounders, and despite improved survival. Similar trends were found after reviewing the literature, and this observation should raise vigilance.
No takes yet. Share an insight, caveat, or question.
Royston et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: